Schilizzi B M, Kroesen B J, The T H, de Leij L
Department of Clinical Immunology, University Hospital, Groningen, Netherlands.
J Immunol Methods. 1992 Aug 30;153(1-2):49-56. doi: 10.1016/0022-1759(92)90304-c.
An in vitro method to increase the production of hapten-specific antibody-forming B cells (AFC) using a carrier-specific T helper hybridoma and murine splenocytes is described. Naive splenocytes (6 x 10(6)/ml) are cultured in vitro in the presence of a hapten-carrier conjugate (DNP.OVA) and OVA-specific T helper hybridomas (0.5 x 10(6)/ml). After 4-5 days in vitro immunization (IVI), the maximum number of DNP-specific AFC were found using a spot-ELISA with twice the number of IgM positive cells as IgG positive AFC. The presence of antigen in the form of a hapten-carrier complex and the use of a carrier-specific Th hybridoma resulted in more hapten-specific AFC than when neither antigen nor Th hybridoma were present or when antigen alone or T help alone were used. Also when the hapten was conjugated to a carrier not recognised by the carrier-specific Th hybridoma there were considerably fewer (less than 50%) hapten specific AFC formed. When in vivo primed splenocytes (DNP) were boosted in vitro (IVB) under the same conditions as for IVI most hapten-specific AFC were found on day 4 and both anti-DNP IgM and IgG AFC were increased relative to IVI. Again most AFC were found when hapten was bound to the relevant carrier. In conclusion, carrier-specific T hybridomas can be used in an in vitro immunization procedure with naive or primed splenocytes to increase the frequency of anti-hapten AFC. This method offers an improvement over the current in vitro immunization procedures for the production of monoclonal antibodies.
本文描述了一种体外方法,该方法利用载体特异性T辅助杂交瘤和小鼠脾细胞来增加半抗原特异性抗体形成B细胞(AFC)的产生。将未成熟脾细胞(6×10⁶/ml)在半抗原-载体偶联物(DNP.OVA)和OVA特异性T辅助杂交瘤(0.5×10⁶/ml)存在的情况下进行体外培养。在体外免疫(IVI)4-5天后,使用斑点ELISA法发现DNP特异性AFC的最大数量,其中IgM阳性细胞数量是IgG阳性AFC的两倍。与既不存在抗原也不存在T辅助杂交瘤,或仅使用抗原或仅使用T辅助细胞时相比,以半抗原-载体复合物形式存在的抗原以及使用载体特异性Th杂交瘤导致产生更多的半抗原特异性AFC。同样,当半抗原与载体特异性Th杂交瘤不识别的载体偶联时,形成的半抗原特异性AFC数量要少得多(少于50%)。当在与IVI相同的条件下对体内经致敏的脾细胞(DNP)进行体外增强(IVB)时,在第4天发现大多数半抗原特异性AFC,并且相对于IVI,抗DNP IgM和IgG AFC均增加。同样,当半抗原与相关载体结合时发现大多数AFC。总之,载体特异性T杂交瘤可用于对未成熟或经致敏的脾细胞进行体外免疫程序,以增加抗半抗原AFC的频率。该方法相对于目前用于生产单克隆抗体的体外免疫程序有所改进。